ACADIA Pharmaceuticals Inc. Overview
ACAD market data
Business OverviewA provider-written description of this company or fund, with its source and observation date.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise into making a difference for underserved neurological and rare disease communities around the world. It has two franchises in neurological and rare diseases. Its neurological disease franchise is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
- Source
- massive
- Observed
- Cadence
- Reference data reviewed periodically
- Status
- fresh
Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.
ACAD price chart · 1M
- O
- 20.90
- H
- 21.10
- L
- 20.59
- C
- 21.04
- Vol
- 27,322.00
Daily history from Jan 4, 2016
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.
- Open
- $20.90
- Previous Close
- $21.22
- Day High
- $21.10
- Day Low
- $20.59
- 52 Week High
- $30.94
- 52 Week Low
- $18.40
- 7 Day Return
- +2.16%
- 30 Day Return
- +7.05%
- 90 Day Return
- -28.44%
- 1 Year Return
- -2.93%
- Daily Notional Volume
- $574.7K Latest daily bar volume multiplied by its closing price.
Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.
- P/E (TTM)
- 9.72 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $2.30 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.85 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 33.4% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $18.39 – $30.96 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $3.7B · P/B 3.68 · P/S 3.25.
Company NewsRecent source-attributed headlines linked to this symbol. Repeated headlines and low-signal items are filtered. Open a headline for its source and context.
10 captured
ACADIA Pharmaceuticals Q3 EPS $0.31 Beats $0.20 Estimate, Sales $342.291M Beat $332.468M EstimateBenzinga ·
Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsightGlobenewswire Inc ·
Decision & ScoreThis analysis is included with a paid membership. Public prices, charts and source-attributed news remain available without a subscription. Membership does not guarantee an investment outcome.
Trend & Pattern EvidenceThis analysis is included with a paid membership. Public prices, charts and source-attributed news remain available without a subscription. Membership does not guarantee an investment outcome.
Sector Peer RankingThis analysis is included with a paid membership. Public prices, charts and source-attributed news remain available without a subscription. Membership does not guarantee an investment outcome.
AI-selected reference, checked against source evidence · Evidence observed
Frequently Asked QuestionsSource-linked answers to common questions about this asset. Check the evidence observation date and whether the reference was reviewed by a person.
- What business does ACADIA PHARMACEUTICALS INC operate?
- Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise into making a difference for underserved neurological and rare disease communities around the world. It has two franchises in neurological and rare diseases. Its neurological disease franchise is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP).
- Which industry is ACADIA PHARMACEUTICALS INC classified in?
- The SEC company record classifies ACADIA PHARMACEUTICALS INC under Pharmaceutical Preparations. This filing classification provides industry context alongside the provider's business description.
What to WatchAI-assisted topics for further research about this asset. These are educational prompts, not trading signals or recommendations.
- Business activities described in the company reference
- Original company disclosures and industry classification